1---2name: managing-attention-deficit-disorders3description: Structures ADHD evaluation in children with behavioral rating scales and medication trials. Use when evaluating pediatric ADHD, interpreting Vanderbilt/Conners scales, or managing stimulant therapy.4---56# Managing Attention Deficit Disorders78Structures the evaluation, diagnosis, and multimodal management of Attention-Deficit/Hyperactivity Disorder (ADHD) in children ages 4-18 using the AAP 2019 Clinical Practice Guideline, DSM-5 criteria, Vanderbilt Assessment Scales, evidence-based medication titration, and behavioral therapy coordination.910## Why This Skill Exists1112ADHD is the most commonly diagnosed neurobehavioral disorder of childhood, affecting approximately 9.4% of U.S. children ages 2-17. Despite high prevalence, it is both overdiagnosed (in populations with access) and underdiagnosed (in girls, minorities, and underserved communities). The AAP 2019 guideline mandates structured diagnostic criteria with multi-informant rating scales, age-stratified treatment recommendations, and systematic titration protocols. This skill enforces the guideline-based diagnostic pathway and treatment algorithm to prevent both missed diagnoses and inappropriate stimulant prescribing.1314---1516## Checkpoint A — Intake Verification1718### Required Intake Questions191. What is the child's age (4-18 for AAP guideline application)?202. What are the primary concerns (inattention, hyperactivity, impulsivity, or combination)?213. In which settings do symptoms occur (home, school, social, sports)?224. When did symptoms first appear (must be present before age 12 per DSM-5)?235. Are there academic problems (grades, IEP/504, retention)?246. Is there a family history of ADHD, mood disorders, anxiety, or substance use?257. Are there symptoms of comorbid conditions (anxiety, depression, ODD, learning disability, tic disorder, ASD)?268. What is the child's sleep pattern (sleep deprivation mimics ADHD)?279. Has the child had vision and hearing screening?2810. Has the child been previously treated with medication for ADHD? What was the response?2930### Required Documents31- Completed Vanderbilt Assessment Scales — Parent form AND Teacher form (or Conners-3, SNAP-IV)32- Academic records (report cards, standardized test scores, teacher comments)33- IEP/504 plan if applicable34- Developmental history35- Prior psychoeducational or neuropsychological testing (if done)36- Vision and hearing screening results3738> DSM-5 requires symptoms in ≥ 2 settings. Teacher input is essential — do not diagnose ADHD without information from the school setting.3940---4142## Step 1 — DSM-5 Diagnostic Criteria4344### Diagnostic Requirements45To diagnose ADHD, ALL of the following must be present:46471. **Symptom threshold**: ≥ 6 of 9 inattention symptoms AND/OR ≥ 6 of 9 hyperactivity-impulsivity symptoms (for age ≥ 17: ≥ 5 in either domain)482. **Duration**: symptoms present for ≥ 6 months493. **Age of onset**: several symptoms present before age 12504. **Pervasiveness**: symptoms present in ≥ 2 settings (home + school)515. **Impairment**: clear evidence that symptoms interfere with functioning526. **Exclusion**: not better explained by another mental disorder5354### ADHD Presentation Types55| Presentation | Criteria |56|-------------|---------|57| Predominantly inattentive | ≥ 6/9 inattention; < 6/9 H-I |58| Predominantly hyperactive-impulsive | < 6/9 inattention; ≥ 6/9 H-I |59| Combined | ≥ 6/9 in both domains |6061### Inattention Symptoms (9)621. Fails to give close attention to details / careless mistakes632. Difficulty sustaining attention in tasks or play643. Does not seem to listen when spoken to directly654. Does not follow through on instructions / fails to finish tasks665. Difficulty organizing tasks and activities676. Avoids or is reluctant to engage in tasks requiring sustained mental effort687. Loses things necessary for tasks698. Easily distracted by extraneous stimuli709. Forgetful in daily activities7172### Hyperactivity-Impulsivity Symptoms (9)731. Fidgets with hands/feet or squirms in seat742. Leaves seat when remaining seated is expected753. Runs about or climbs in inappropriate situations764. Unable to play or engage in leisure activities quietly775. "On the go" / acts as if "driven by a motor"786. Talks excessively797. Blurts out answers before questions are completed808. Difficulty waiting turn819. Interrupts or intrudes on others8283---8485## Step 2 — Vanderbilt Assessment Scale Interpretation8687### Parent Vanderbilt (NICHQ Vanderbilt Assessment Scale — Parent Informant)88- 55 items covering: inattention (9 items), hyperactivity/impulsivity (9 items), ODD (8 items), conduct disorder (14 items), anxiety/depression (7 items), and performance (8 items)89- Symptom scoring: 0 = Never, 1 = Occasionally, 2 = Often, 3 = Very Often90- Symptom is "positive" if scored 2 (Often) or 3 (Very Often)91- ADHD screen positive: ≥ 6 of 9 inattention AND/OR ≥ 6 of 9 H-I items scored ≥ 292- Performance impairment: ≥ 1 performance item scored 4 or 5 (somewhat/problematic)9394### Teacher Vanderbilt (NICHQ Vanderbilt Assessment Scale — Teacher Informant)95- 43 items: inattention (9), H-I (9), ODD/conduct (10), anxiety/depression (7), academic performance (3), classroom behavior (5)96- Same scoring and threshold criteria as parent form97- Academic performance: scored 1-5 (excellent to problematic)9899### Concordance Analysis100- Both parent AND teacher must show symptom endorsement for ADHD diagnosis101- If only one setting endorses symptoms: investigate setting-specific factors (classroom structure, teacher expectations, home environment)102- If discordant: consider alternative diagnoses (anxiety, learning disability, trauma)103104### Comorbidity Screening (Built Into Vanderbilt)105- ODD screen: ≥ 4 of 8 items scored ≥ 2 + performance impairment106- Conduct disorder screen: ≥ 3 of 14 items scored ≥ 2 + performance impairment107- Anxiety/depression screen: ≥ 3 of 7 items scored ≥ 2 + performance impairment → warrants formal evaluation108109---110111## Step 3 — Age-Stratified Treatment (AAP 2019)112113### Ages 4-5 (Preschool)114- **First-line**: parent-administered behavior therapy (evidence-based parent training programs)115- **Medication**: methylphenidate may be prescribed if behavioral therapy is insufficient and symptoms cause moderate-to-severe functional impairment116- Avoid amphetamines as first-line in this age group (less evidence)117118### Ages 6-11 (School-Age)119- **First-line**: FDA-approved medication for ADHD AND/OR evidence-based behavioral therapy (preferably both)120- AAP recommends medication + behavioral therapy as optimal combined treatment121- Teacher-delivered behavioral strategies (daily report card, classroom accommodations)122123### Ages 12-18 (Adolescent)124- **First-line**: FDA-approved medication with assent from the adolescent125- Behavioral therapy should be offered, but medication is the primary treatment126- Address driving safety, substance use risk, and organizational skills127- Discuss medication continuity through transitions (college, employment)128129---130131## Step 4 — Medication Management132133### Stimulant Medications (First-Line)134135#### Methylphenidate Formulations136| Formulation | Brand Examples | Duration | Starting Dose |137|-------------|---------------|----------|---------------|138| Immediate-release | Ritalin | 3-4 hours | 5 mg BID-TID |139| Extended-release (OROS) | Concerta | 10-12 hours | 18 mg QAM |140| Extended-release (beaded) | Ritalin LA, Aptensio XR | 8-10 hours | 10-20 mg QAM |141| Transdermal patch | Daytrana | 10-12 hours | 10 mg/9 hr patch |142| Liquid | Quillivant XR | 10-12 hours | 20 mg QAM |143144#### Amphetamine Formulations145| Formulation | Brand Examples | Duration | Starting Dose |146|-------------|---------------|----------|---------------|147| Mixed amphetamine salts IR | Adderall | 4-6 hours | 5 mg QD-BID |148| Mixed amphetamine salts XR | Adderall XR | 10-12 hours | 5-10 mg QAM |149| Lisdexamfetamine | Vyvanse | 12-14 hours | 20-30 mg QAM |150| Dextroamphetamine | Dexedrine | 4-6 hours | 2.5-5 mg BID |151152### Titration Protocol1531. Start at the lowest recommended dose1542. Titrate every 1-2 weeks based on response and side effects1553. Use Vanderbilt Follow-Up scales (parent + teacher) to assess response1564. Target: symptom reduction to < 6 positive items in affected domains + improved performance1575. If one stimulant class fails (methylphenidate): switch to amphetamine class (and vice versa) before moving to non-stimulant158159### Non-Stimulant Medications (Second-Line)160| Medication | Class | Starting Dose | Notes |161|-----------|-------|---------------|-------|162| Atomoxetine | NRI | 0.5 mg/kg/day × 3 days → 1.2 mg/kg/day | Onset 4-6 weeks; FDA black box: suicidal ideation monitoring |163| Guanfacine XR | Alpha-2 agonist | 1 mg QHS | Sedation, hypotension; do not abruptly discontinue |164| Clonidine XR | Alpha-2 agonist | 0.1 mg QHS | Similar to guanfacine; also treats tics |165| Viloxazine XR | NRI | 100 mg QAM (6-11y); 200 mg QAM (12+) | Newer; less data on long-term outcomes |166167### Side Effect Monitoring168- **Every visit**: weight, height, heart rate, blood pressure169- **Appetite suppression**: most common side effect; counsel on high-calorie breakfast, after-medication meals, bedtime snacks170- **Growth**: plot height and weight on growth chart at every visit; calculate height velocity annually; temporary growth deceleration is common171- **Sleep**: stimulants may cause insomnia; consider earlier dosing, shorter-acting formulation, or melatonin adjunct172- **Cardiovascular**: routine ECG NOT recommended for healthy children; obtain ECG only if cardiac history, family history of sudden death, or abnormal cardiac exam173- **Tics**: stimulants may unmask but generally do not cause tics; tics are not an absolute contraindication174- **Mood/behavior**: monitor for rebound irritability, emotional lability, new anxiety175176---177178## Step 5 — Behavioral and Academic Interventions179180### Evidence-Based Behavioral Therapy181- **Parent training programs**: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)182- **Classroom interventions**: daily report card (DRC), preferential seating, extended time, reduced homework load, frequent breaks183- **Social skills groups**: peer interaction training (for children with social impairment)184- **Organizational skills training**: for ages 8+ (homework routines, planner use, time management)185186### School Accommodations187- Section 504 plan: ADHD qualifies as a disability under Section 504188- IEP: if ADHD causes specific learning disability requiring specialized instruction (under IDEA category "Other Health Impairment")189- Common accommodations: extended time on tests, preferential seating, reduced homework, movement breaks, behavior intervention plan190191---192193## Checkpoint B — ADHD Management Review194195- [ ] DSM-5 criteria systematically evaluated and documented196- [ ] Symptoms confirmed in ≥ 2 settings (parent + teacher Vanderbilt)197- [ ] ADHD presentation specified (inattentive, H-I, combined)198- [ ] Comorbidities screened (ODD, conduct, anxiety, depression, learning disability)199- [ ] Age-appropriate treatment initiated (behavioral therapy for 4-5; medication ± behavioral for 6+)200- [ ] Medication selected, dose documented, titration plan specified201- [ ] Side effect monitoring documented (weight, height, HR, BP)202- [ ] Follow-up Vanderbilt scales collected from parent AND teacher203- [ ] School accommodations addressed (504 or IEP discussion)204- [ ] Driving safety discussed (if adolescent)205- [ ] All [VERIFY] flags resolved or escalated206207---208209## Quality Audit210211| Item | Requirement | Pass? |212|------|-------------|-------|213| Multi-informant data | Parent AND teacher Vanderbilt/Conners completed | |214| DSM-5 compliance | All 6 diagnostic criteria explicitly addressed | |215| Presentation specified | Inattentive / H-I / Combined documented | |216| Comorbidity screen | ODD, anxiety/depression at minimum screened | |217| Age-appropriate Tx | Behavioral therapy first for 4-5; combined for 6+ | |218| Titration plan | Starting dose, target, timeline for reassessment | |219| Growth monitoring | Weight and height plotted at each medication visit | |220| Vital signs | HR and BP documented at each medication visit | |221| School coordination | 504/IEP addressed or discussed | |222| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |223224---225226## Guidelines227228- Follow AAP 2019 Clinical Practice Guideline: Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents229- Use DSM-5 criteria for ADHD diagnosis (APA 2013)230- NICHQ Vanderbilt Assessment Scales: recommended by AAP for initial evaluation and follow-up monitoring231- Stimulant titration: start low, go slow, use rating scales to measure response objectively232- MTA study (Multimodal Treatment Study of ADHD): combined medication + behavioral therapy superior to either alone for school-age children233- AAP: no routine ECG for ADHD medication initiation in healthy children without cardiac risk factors234- FDA black box: atomoxetine — monitor for suicidal ideation, particularly in first months235- Alpha-2 agonists: do not abruptly discontinue (rebound hypertension risk)236- Substance abuse: treated ADHD reduces substance abuse risk; untreated ADHD increases it237- ADHD is a chronic condition: treatment should not be discontinued without structured medication holiday and reassessment238- This skill produces clinical documentation; it does not replace clinical judgment